KSL Diagnostics INC

KSL Diagnostics INC was paid $3.81M by Medicaid between May 2020 and Sep 2023, across 7 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 80% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New York

Rank by total paid#36 of 116

Median peer was paid$618K

This provider vs. median6.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	11,659	$1.07M
2021	45,279	$1.82M
2022	26,413	$889K
2023	1,244	$28K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	80%	38,766	29,268	$3.04M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	19%	29,524	24,914	$718K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	11,339	10,095	$28K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	4,730	4,452	$21K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	169	97	$3K
86769		<1%	22	12	$1K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	45	45	$307.90

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSURESH, LAKSHMANAN (CSO)